Search

Displaying results 3311 - 3320 of 6951 in total
  1. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263] … Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263].

  2. Target

    Transmembrane anterior posterior transformation protein 1 homolog

    go.drugbank.com/bio_entities/BE0003506
    TargetHumans

    Plays a role in primary cilia formation (PubMed:26365339). May act as a downstream effector of HOXC8 possibly by transducing or transmitting extracellular information required for axial skeletal patterning during development (By similari...

    Synonyms: Cytomegalovirus partial fusion receptorFunction: growth hormone-releasing hormone receptor activity
  3. Drug

    Ceftibuten

    go.drugbank.com/drugs/DB01415
    ApprovedInvestigational

    Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Ximelagatran

    go.drugbank.com/drugs/DB04898
    ApprovedWithdrawn

    Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.

  5. Drug

    IL-2 pDNA

    go.drugbank.com/drugs/DB05935
    Experimental

    Vical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma

  6. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    It was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … [A262011,A262591] Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.[L48696]

    Categories: Programmed Death Receptor-1 Blocking Antibody
  7. Drug

    Crofelemer

    go.drugbank.com/drugs/DB04941
    ApprovedInvestigational

    It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.

  8. Drug

    Streptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16710
    ApprovedInvestigational

    It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection.

  9. Target

    Ribosome-binding protein 1

    go.drugbank.com/bio_entities/BE0003466
    TargetHumans

    Acts as a ribosome receptor and mediates interaction between the ribosome and the endoplasmic reticulum membrane

    Synonyms: Ribosome receptor protein, 180 kDa ribosome receptor homolog
  10. Target

    Natural killer cells antigen CD94

    go.drugbank.com/bio_entities/BE0010559
    TargetHumans

    Immune receptor involved in self-nonself discrimination.

    Synonyms: NK cell receptor, Killer cell lectin-like receptor subfamily D member 1Function: HLA-A specific activating MHC class I receptor activity